Anzeige
Mehr »
Donnerstag, 02.10.2025 - Börsentäglich über 12.000 News
Starkes Upside-Potenzial: Wachstumsstory mit starken Gehalten und großem Explorationspotenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A143G8 | ISIN: FR0013018124 | Ticker-Symbol: NXOA
München
02.10.25 | 08:04
0,367 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
NICOX SA Chart 1 Jahr
5-Tage-Chart
NICOX SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,3630,36909:32

Aktuelle News zur NICOX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07:34NICOX SA: Nicox's NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations220Press Release Nicox's NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Additional pre-planned analysis of the NCX 470 Denali...
► Artikel lesen
04.09.Nicox Projects Full Debt Repayment By 20263
04.09.NICOX SA: Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed569Press Release Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed Company expects to fully repay existing financial debts in 2026NCX 470 NDA submissions...
► Artikel lesen
26.08.NICOX SA: Nicox Announces Shareholder Q&A Webpage Available287Press Release Nicox Announces Shareholder Q&A Webpage AvailableAugust 26, 2025 - release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international...
► Artikel lesen
21.08.Nicox plans filings for glaucoma after phase 3 win3
NICOX Aktie jetzt für 0€ handeln
21.08.NICOX SA: Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients341Press Release Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Achieving the primary endpoint in both Denali and the first NCX 470 Phase 3 trial, Mont...
► Artikel lesen
08.08.NICOX SA: Nicox Extends Existing Flexible Equity Financing487Press Release Nicox Extends Existing Flexible Equity Financing 5 million shares added to the existing equity financing line with Vester Finance NCX 470 Denali confirmatory Phase 3 results expected...
► Artikel lesen
05.08.NICOX SA: Nicox's Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan426Press Release Nicox's Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment...
► Artikel lesen
17.07.Nicox Grants Kowa Rights To Develop, Commercialize NCX 4702
17.07.NICOX SA: Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories503Press Release Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories €7.5 million upfront, with...
► Artikel lesen
30.06.NICOX SA: Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial502Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to mid-September 2025 New Drug Application (NDA) submission in...
► Artikel lesen
06.06.NICOX SA: Nicox: Notice of the Ordinary and Extraordinary Shareholders' Meeting on June 27, 2025 and appointment of an ad hoc representative4
27.05.NICOX SA: Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan768Press Release Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan Exclusive Japanese partner Kowa has received...
► Artikel lesen
14.05.Nicox Reports Positive Phase 3b Trial Results For NCX 470 In Intraocular Pressure Reduction2
14.05.NICOX SA: Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial449Press Release Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Several aqueous humor parameters stimulated by nitric oxide were statistically significant or trended...
► Artikel lesen
30.04.Nicox reports FY results1
30.04.NICOX SA: Nicox Provides Full Year 2024 Financial Results409Press Release Nicox Provides Full Year 2024 Financial Results Nicox SA revenue of €7.9 million for full year 2024 Exceptional income of €13.7 million following the transfer of VYZULTA's future...
► Artikel lesen
19.03.NICOX SA: Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial561Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last patient in the U.S. in the ongoing NCX 470 Denali...
► Artikel lesen
06.03.NICOX SA: Nicox Extends Cash Runway into Q4 2025956Press Release Nicox Extends Cash Runway into Q4 2025 Flexible equity financing line with Vester Finance of up to 10,000,000 shares over 24 monthsImmediate upfront payment from Vester Finance...
► Artikel lesen
03.03.NICOX SA: Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update556Press Release Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update More patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal...
► Artikel lesen
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1